Category: Olaparib

In this article, we will discuss Olaparib (Dose Adjustments). So, let’s get started. Dose Adjustments for Adverse Reactions To manage adverse reactions, consider interruption of treatment or dose reduction. The recommended dose reduction is 250 mg (one 150 mg tablet and one 100 mg tablet) taken twice daily, for a total daily dose of 500 […]

In this article, we will discuss Olaparib (Patient Selection-2). So, let’s get started. Patient Selection for gBRCAm HER2-negative Metastatic Breast Cancer Select patients for the treatment of HER2-negative metastatic breast cancer with Lynparza based on the presence of deleterious or suspected deleterious gBRCA-mutation.

In this article, we will discuss Olaparib (Patient Selection-1). So, let’s get started. Patient Selection for gBRCAm Advanced Ovarian Cancer Select patients for the treatment of advanced ovarian cancer with Olaparib based on the presence of deleterious or suspected deleterious BRCA-mutations.

In this article, we will discuss Olaparib (Dosage-1). So, let’s get started. Olaparib is also available as a 50 mg capsule. DO NOT substitute Olaparib tablets (100 mg and 150 mg) with Olaparib capsules (50 mg) on a milligram-to-milligram basis due to differences in the dosing and bioavailability of each formulation.

In this article, we will discuss Olaparib (Usage-3). So, let’s get started. Germline BRCA-mutated HER2-negative Metastatic Breast Cancer Olaparib is indicated in patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have […]